SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Korea Agro-Fisheries and Food Trade Corporation (aT) continues to champion the excellence of Korean produce in Singapore with its latest showcase — an exclusive event celebrating premium Korean rice and fruits. The event, held yesterday at The Butcher’s Dining, featured a live cooking demonstration and tasting session, offering attendees a firsthand experience of Korea’s finest agricultural products. The event was graced by the presence of Song Mi-Ryung, the Minister of Agriculture, Food and Rural Affairs of South Korea and Hong Jin-Wook, the Ambassador of the Republic of South Korea to Singapore.Clockwise from Top Left Image: Korean Culinary Masterclass Held at The Butcher's Dining, Minister Song Interacting with Masterclass guests, Korean Fresh Zone at CS Fresh at Great World City, Minister Song Browsing Products at the Korean Fresh ZoneSince its establishment in 1967, aT has played a pivotal role in promoting Korean food products worldwide, fostering deeper appreciation through strategic events and brand partnerships. With the growing demand for high-quality international produce in Singapore, aT aims to introduce more consumers to the unique textures, flavors, and versatility of Korean rice and fruits.Distinctive Korean FlavoursKorean cuisine is celebrated not only for its bold flavors but also for its numerous health benefits, thanks to its emphasis on fresh, nutrient-rich ingredients and time-honored culinary traditions. A cornerstone of Korean food is its use of fermented ingredients such as kimchi and doenjang (soybean paste), which are packed with probiotics that support gut health, improve digestion, and enhance overall well-being. These naturally fermented foods contribute to a balanced diet, aligning with the increasing consumer focus on digestive health and immune-boosting nutrition.Renowned for its chewy texture and exceptional quality, Korean rice has established itself as a distinctive staple in Singapore’s culinary landscape, setting it apart from varieties such as Thai jasmine rice and Vietnamese broken rice. Naturally gluten-free and rich in essential nutrients, Korean rice as well as rice products serves as the foundation for many beloved dishes, including bibimbap, tteokguk, and tteokbokki. Bibimbap stands out as a nutritionally balanced dish, featuring a vibrant medley of Korean vegetables that are high in fiber, vitamins, and antioxidants – key elements of a health-conscious diet. The focus on fresh, seasonal ingredients aligns with the growing global demand for healthier food choices, as reported by The Business Research Company, the functional foods market is projected to expand from $281.3 billion in 2024 to $315.1 billion in 2025, reflecting a robust compound annual growth rate (CAGR) of 12%.Beyond staple grains, Korean fruits such as Shine Muscat grapes and premium strawberries have gained international recognition for their exceptional sweetness and quality. Frequently used in both savory and dessert dishes, these fruits are not only a treat for the palate but also rich in antioxidants and vitamin C, further reinforcing the health benefits of Korean cuisine. As consumers worldwide increasingly prioritise immune-boosting foods, the demand for nutrient-dense Korean ingredients continues to rise.Premium K-Food Exhibition: A Display of Various Korean Rice Products as well as Other Korean ProduceAt the event, a stunning display of premium K-Food export products took center stage. From Korean rice and rice-based products to traditional liquors and premium fruits such as Korean strawberries and Shine Muscat grapes, the showcase offered a rich selection of Korea’s finest ingredients. A standout highlight was the introduction of 12 traditional Korean liquors, specially airlifted from Korea for this event. These liquors, many of which had never been exported to Singapore before, showcased the incredible diversity of Korean traditional brews, featuring unique ingredients such as plum, lingzhi, pine and yuzu, all crafted with a base of Korean rice.Adding to the excitement was the Baba Gimbap, a product that made waves after selling out in major U.S. retail stores in 2023. Visitors also had the chance to discover a variety of rice-based delicacies, including porridge, tteokbokki, and rice cakes.The fresh produce display corner was undoubtedly the centerpiece of the event. Featuring Korean-grown rice, renowned for its superior quality, alongside premium Korean strawberries and Shine Muscat grapes, the display highlighted some of Korea’s most coveted agricultural treasures. With their vibrant colors and pristine presentation, these premium ingredients created a stunning visual showcase, embodying the essence of luxury and excellence. Guests had the opportunity to explore these exquisite products up close, further deepening their appreciation for the richness of Korean fresh produce.A Culinary Showcase: Korean Ingredients in Everyday CookingThe event featured a live cooking demonstration led by esteemed culinary instructor Kim Hyuna, who guided attendees through the preparation of four signature dishes incorporating Korean ingredients, including premium rice and fruits:Bibimbap – A classic Korean mixed rice dish featuring a vibrant assortment of seasonal local and Korean vegetables and a rich, flavourful gochujang (red chili paste) sauce.Gungjung Tteokbokki – A royal court-style variation of the popular dish that showcases the diversity of tteokbokki by incorporating an assortment of vegetables. The combination of fresh ingredients and the chewy texture of tteok creates a harmonious blend of flavors.Tteokguk – Despite being a staple in Korean cuisine, tteokguk remains relatively unknown overseas. This dish is prepared by simmering beef until tender in a deeply flavourful broth and seasoned with a simple yet refined touch, tteokguk is the quintessential New Year’s dish, comforting, satisfying, and rich in cultural significance.Nurungji Ice Cream – A unique dessert crafted from nurungji (crispy scorched rice) and millet powder. Soft ice cream is paired with crunchy nurungji crackers and a dusting of warm millet powder, drawing inspiration from the Western affogato. Seasonal Korean strawberries or Shine Muscat grapes are added as toppings for a refreshing twist.Guests also had the opportunity to savour these dishes alongside traditional Korean wine pairings, enhancing their appreciation of the depth and complexity of Korean cuisine.A Commitment to Elevating Korean Produce in SingaporeSpeaking at the event, Song Mi-Ryung, Minister of Agriculture, Food and Rural Affairs of South Korea, remarked, “As we celebrate the 50th anniversary of diplomatic relations between South Korea and Singapore, we are deeply honored to host this event, showcasing the best of Korean cuisine in Singapore. We have carefully curated four special menus featuring premium Korean rice and rice products, fresh strawberries and shine muscat grapes, all grown in Korea’s distinct four seasons, paired with traditional liquors that perfectly complement each dish. We hope that many in Singapore will come to appreciate and enjoy these exceptional Korean ingredients, from rice-based delicacies to our vibrant fruits and time-honored liquors. This event reaffirms aT’s dedication to enhancing awareness and accessibility of Korean produce in Singapore. By showcasing the superior quality and versatility of Korean rice and berries, we aim to strengthen our presence in the market and inspire more consumers to embrace the rich and diverse flavors of Korea.”Korean Fresh Zone: Masterclasses and more at CS Fresh at Great World CityBuilding on the excitement around Korean fresh produce, aT, in partnership with CS Fresh at Great World City, will be hosting the Korean Fresh Zone Promotion from 20 to 26 March.Renowned chef Daren Teo – better known online as @thepantryboy – will be leading a series of exclusive masterclasses, showcasing the art of preparing iconic Korean dishes such as Japchae, Kimchi-jjigae, Boseot Jeongol and delectable Korean-inspired desserts like fruit tarts. With a background that includes training in France under a three-Michelin-starred chef and experience at the Michelin-starred restaurant Burnt Ends, Chef Daren will share expert techniques using the finest Korean fresh produce available at the Korean Fresh Zone in CS Fresh at Greeat World City, including over 40 varieties of vegetables and mushrooms, as well as premium Korean strawberries and Shine Muscat grapes. The masterclasses will be hosted by Eric Youn (@esyfilms), a beloved content creator known as the "Korean Oppa from Singapore”, attendees will get to sample some of the dishes and even stand a chance to win exclusive giveaways!Shoppers who spend $30 or more on Korean Fresh Zone produce, Korean strawberries or Shine Muscat grapes will receive a complimentary set of three chocolate-coated strawberries from chocolate boutique, BerryBar. Shoppers can choose from available designs in-store, while stocks last.Don't miss this exciting celebration of Korean flavors at CS Fresh!For more information on upcoming events and partnerships by aT, please visit www.at.or.kr.About the Korea Agro-Fisheries and Food Trade Corporation (aT)Established in 1967, the Korea Agro-Fisheries and Food Trade Corporation (aT) is a key government agency dedicated to advancing the global trade, export, and marketing of Korean foods and beverages. With a mission to elevate Korean agricultural products and culinary culture worldwide, aT leverages strategic partnerships and innovative strategies to promote Korean products while adapting to key trends, benefiting both producers and consumers. Copyright 2025 ACN Newswire via SeaPRwire.com.

TAIPING, Malaysia, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - This Hari Raya Aidilfitri, Spritzer invites Malaysians to celebrate the heart of the season by creating new, happy memories through simple, thoughtful acts of understanding and kindness. In conjunction with the 2025 Hari Raya celebrations, from 21st March to 20th April 2025, the Spritzer EcoPark has been freshly adorned, transforming it into a festive sanctuary where families and friends can come together, reconnect, and reflect.Photo 1: One of Spritzer EcoPark DecorationsSpritzer’s dazzling decorations feature a blend of classic Malay motifs with floral elements through seven unique setups. Many of the designs incorporate upcycled decorations, showcasing sustainability alongside artistry. One of the setups features a lush, flower-adorned bower that adds to the enchanting atmosphere. Moon and star elements, synonymous with Islam, are also woven throughout the designs. With intricate details and glowing elements, the decorations create a captivating experience that is just as stunning during the day as it is at night. Entry to the Spritzer EcoPark remains free for all!“Celebrations are about more than just coming together; it is about understanding and highlighting things that bring joy to our lives and loved ones. This year’s theme is about celebrates thoughtfulness through simple acts of kindness and care,” said Winnie Chin, Head of Public Relations of Spritzer. “At Spritzer, we believe that true celebration comes from thoughtful gestures, whether it is spending quality time, nourishing our families, or simply creating a space for everyone to enjoy nature at its best. Spritzer EcoPark was preserved for this purpose – a legacy where people can connect, reflect, and celebrate surrounded by the tranquillity of nature.”Photo 2: Spritzer EcoPark decorations with traditional Malay elementsSpritzer EcoPark offers a variety of engaging activities for all ages to add onto the festive atmosphere. Families can enjoy mini golf, paddle kart rides, and creative DIY crafts, making this celebration one of shared laughter and meaningful connections. The Snack Station provides delicious treats at affordable prices, while the Water Shop ensures that guests can stock up on Spritzer’s refreshing products and try out the new Spritzer Hari Raya recipes for their Raya gatherings. Unique souvenirs will also be available at the Souvenir Shop, allowing visitors to take home a special memento of their time at the park.Photo 3: Spritzer EcoPark Decorations at nightWishing you a joyous Hari Raya from Spritzer EcoPark! Whether you are here for fun, relaxation, or a refreshing escape, we are ready to make your celebration even more special.The park is open daily from 10:00 AM to 9:30 PM. We are located at Lot 898, Jalan Reservoir, Off Jalan Air Kuning, 34000 Taiping, Perak.For more updates and details, follow Spritzer EcoPark on Facebook and Instagram. – End–About SpritzerSpritzer, Malaysia’s No.1 bottled water brand since 1989, sources its water from a 430-acre tropical rainforest in Taiping. The water undergoes a natural filtration process through underground rocks for over 15 years, enriching it with essential minerals like Silica, which benefits skin, bones, hair, and nails.As a leader in smart manufacturing, we use advanced technology to ensure quality and safety. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to sustainability. Tested annually by SIRIM, our products are free from microplastics.Spritzer offers a full range of products, from Natural Mineral Water and Sparkling Water to Distilled Water and Fruit-flavoured Beverages, catering to every lifestyle and occasion. With a vision to become a circular brand by 2030, we are committed to sustainability and delivering quality you can trust.Spritzer—nature, innovation, and sustainability in every bottle. For more information, please visit www.spritzer.com.my. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights:Hiring activity in Singapore saw recovery with a 3% month-on-month growth while witnessing an annual dip of 5% in February’25Advertising, Public Relations & Media sector and the Education sector lead with 7% month-on-month growth in February '25Hiring for Software, Hardware, and Telecom roles record the highest growth at 2% month-on-month Legal sector saw the strongest annual growth at 19% year-on-yearSINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - foundit (formerly Monster APAC & ME), one of the leading jobs and talent platform, today published the foundit Insights Tracker (fit) Singapore for February 2025. The Singapore fit report highlights growth in the Advertising and Education sectors alongside rising demand for technology professionals.The tracker reveals an overall year-on-year (YoY) decline of 5% in hiring activity across sectors, as the index dropped from 108 in February 2024 to 103 in February 2025. However, a month-on-month (MoM) analysis indicates a 3% uptick,Commenting on Singapore's job trends for February 2025, V Suresh, CEO, foundit, said,“The February 2025 foundit Insights Tracker signals a promising recovery in Singapore’s job market. While year-on-year figures reflect ongoing economic recalibration, the month-on-month growth indicates a resurgence in hiring activity. The robust expansion of sectors such as Advertising, Media, and Education, coupled with the growing demand for technology professionals, underscores shifting industry priorities and workforce evolution. As digital transformation accelerates, Singapore’s job landscape is stabilizing, with a strong emphasis on upskilling, adaptability, and future-ready talent."Advertising, and Education sectors lead industry growth, while Engineering and Retail sectors show strong improvementsThe Advertising, Market Research, Public Relations, Media, and Entertainment sector has emerged as a frontrunner in e-recruitment activity among all monitored industries, showing a 7% MoM growth in February 2025. This growth is driven by increased digital marketing efforts and brand-building strategies.Equally impressive, the Education sector also recorded 7% MoM growth in February 2025, reflecting a continued emphasis on workforce upskilling and professional development.Following these leaders, the Engineering, Construction, and Real Estate sector showed positive trends with 6% MoM growth, while the Retail, Trade, and Logistics sector experienced 5% MoM growth, both driven by sustainability initiatives and evolving business needs.Several sectors show modest growth while others remain stableThe Production/Manufacturing, Automotive, and Ancillary sector demonstrated positive hiring momentum with 5% MoM growth in February 2025.Several sectors showed more modest growth, with Hospitality & Travel, IT, Telecom/ISP, and BPO/ITES, BFSI, and Healthcare all registering 2% MoM increases, signalling steady job creation across these industries.Conversely, multiple sectors including Oil and Gas, Import/Export, Shipping/Marine, Government/PSU/Defence, and Consumer Goods/FMCG exhibited stagnant hiring activity with 0% MoM change.Technology roles lead demand among functionsIn terms of functions, Software, Hardware, and Telecom witnessed the highest demand in February 2025, with a 2% MoM increase. This trend underscores the growing need for tech talent amid ongoing digital transformation initiatives.Marketing & Communications, HR & Admin, Engineering/Production, Sales & Business Development, Medical Roles, and Legal roles all showed modest but positive growth at 1% MoM, indicating broad but measured hiring activity across professional functions.The roles in Legal experienced a robust 19% YoY increase in hiring activity, highlighting the rising need for legal professionals amid evolving regulatory landscapes, corporate expansions, and compliance requirements.However, Hospitality Roles, Customer Service, Finance & Accounts, and Purchase/Logistics/Supply Chain roles saw no changes (0% MoM), reflecting a period of stability in workforce demand across these functions.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring. Additionally, foundit has been recognised as a Great Place to Work, reflecting its dedication to fostering a supportive and dynamic work culture.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月24日 - (亚太商讯 via SeaPRwire.com) - "十四五"开篇以来，能源央企深入落实习近平总书记关于能源安全和绿色发展的一系列重要论述，统筹"保障能源安全"和"绿色低碳转型"两大任务，积极贯彻国家"双碳"战略，全力推动高质量发展。中国电力（02380）作为国家电投旗下清洁能源旗舰上市平台，是电力企业清洁转型和高质量发展方面最具有代表性的上市公司之一。智通财经APP了解到，中国电力3月20日发布2024年业绩公告，并在3月21日召开业绩发布会。该公司全年实现收入542.13亿元，同比增长22.48%，其中清洁能源收入322亿元，占总收入60%，同比提升了9个百分点。实现权益持有者应占利润38.62亿元，经营性净利润创上市以来历史新高。合并装机容量达到4939.1万千瓦，其中清洁能源占比80.12%。该公司计划宣派2024年度股息人民币0.162元/股，派息率60%；加上2024中期特别股息0.05元/股，全年派息总额0.212元/股，派息率达到78%，对应股息率超过7.7%。四年"翻一番"，能源转型和业绩增长全面提速2021年，中国电力发布全新战略，步入清洁发展和创新驱动的转型快车道，清洁能源装机占比快速提升、资产质量持续优化、科技创新形成新的支撑，形成了清洁发展与科技创新"双轮驱动"、水火风光协同互济的发展格局。存量提质方面，成功对超600万千瓦亏损煤电开展煤电联营，快速堵住经营业绩"出血点"，煤电板块度电盈利能力已从行业中下游跃升至领先地位。从转型的成效来看，2021年以来，该公司实现4年"翻一番"：合并装机容量增加85%，资产总额增加118%，营业收入增长91%，归母净利润增长126%。聚焦科技创新与核心竞争力，扎实推进战新产业发展2021年以来，中国电力科技创新全面提速，在新型储能、储能安全、新型电力系统建设关键技术等领域掌握了一批技术。在新型储能领域，新源智储已获评北京市"独角兽"，牵头建设应急管理部电化学储能安全重点实验室，推出了"智储-银河"系列超分子全浸没式工商业储能一体机，从源头上切断了发生火灾的可能性；在绿电交通领域，启源芯动力市场占有率保持行业领先，C轮融资投后估值达100亿元；在清洁供暖和地热领域，新源泰利建成房山区首个100%可再生能源供热制冷项目，获批共建地热院士专家工作站。分红金额逐年上升，以实际行动回馈股东2021-2024年，该公司每股派息从0.05元上升至0.162元，2021年利润受到火电的影响而亏损，但该公司依旧坚持派息，2022年恢复盈利后，三年的平均派息比例超过60%。拉长周期看，根据东方Choice数据，2004年以来该公司累计派息21次，平均派息比例达56.91%，在业内处于领先水平。而在分红的持续增长下，目前其股息率已具较大吸引力。高度重视资本市场，市值表现取得显著突破2021年以来，中国电力密集开展资产结构调整、收购母公司资产、股权激励、母公司增持、ESG管理、投资者关系等工作，在资本市场关注度逐渐提升。2021-2022年，中国电力股价上涨超过3倍，市值最高超过600亿港币，之后2年受大环境以及电力政策影响有所回撤。该公司管理层称，将全面加强市值管理，落实国资委关于加强中央企业控股上市公司市值管理工作的各项意见，研究各项市值管理工具利用，加大重视股东回报。值得注意的是，该公司持续获得各方看好：大股东国家电投近年持续开展增持；中信金融资产于2024年举牌并获得1名董事席位；而港股通资金也在持续流入，其中沪港通于最近60日净买入1.62亿股，截止3月21日持股比例13.78%，较2021年增长约10个百分点。此外，该公司也获得多家境内外投行看好，给予目标价均显著高于现价。综合来看，"十四五"开篇至今，中国电力加速内功修炼，向市场交出了一份靓丽的成绩单。在算力需求呈指数级增长导致全球开启电力竞赛的背景下，在能源政策支持电力企业高质量发展的趋势下，电力公司在资本市场有望获得估值回归。而中国电力凭借自身战略、资产结构等差异化优势，有望迎来更好的投资机会。 Copyright 2025 亚太商讯 via SeaPRwire.com.

SAN DIEGO, CA, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI), a world leader in unmanned aircraft systems (UAS), has received the prestigious EMAR/FR 145 Maintenance Organization Approval for component maintenance from the French Military Continuing Airworthiness Authority, DSAE. This approval underscores GA-ASI's commitment to the highest standards of safety, compliance, and operational excellence in military aviation.The EMAR framework is a set of regulations developed from commercial aerospace standards (FAA/EASA) that are designed to ensure airworthiness for European military aircraft. It establishes a common airworthiness framework recognized by military airworthiness authorities worldwide. EMAR/FR 145 certification authorizes maintenance organizations to perform critical maintenance tasks while ensuring strict adherence to safety, reliability, and documentation requirements.GA-ASI's EMAR/FR 145 approval allows the company to issue EMAR Form 1s (Return to Service forms) for components serviced by the approved maintenance organization, confirming the safety and airworthiness of the equipment. This recognition applies to GA-ASI's maintenance activities at its Poway and Adelanto, California, facilities and covers CAT C (component maintenance) services."This approval is a significant achievement for GA-ASI, positioning the company to better serve international customers, especially military users of our MQ-9A and MQ-9B UAS platforms," said Sam Richardson, GA-ASI vice president of Sustainment. "The ability to leverage the EMAR/FR 145 certification streamlines the company's processes, reduces costs, and accelerates future airworthiness pursuits, as many future customers will recognize this certification rather than requiring a full, independent certification process."By obtaining EMAR/FR 145 approval, GA-ASI further demonstrates its ability to meet the stringent demands of the global defense market. The framework's widespread recognition ensures that GA-ASI can expand operations and offer high-quality, compliant maintenance services to international customers, ultimately driving company growth in global markets.This certification offers significant operational and financial benefits for both GA-ASI and its customers. For GA-ASI, the approval reduces future oversight costs by leveraging the DSAE Audit Team's oversight activities, ensuring a more efficient and cost-effective certification process for future non-French EMAR customers. For customers, the EMAR/FR 145 approval provides a framework recognized internationally, offering a streamlined maintenance certification process. The recognition agreements between EMAR and non-EMAR countries allow future customers to leverage GA-ASI's French approval, saving time and resources compared to a full certification effort.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

- ComfortDelGro, a leading multi-modal mobility transport operator, introduces a new purpose statement to reflect its commitment to driving positive impact for a better future. - Refreshed logo and corporate identity underscores the company’s journey as a global, progressive, and collaborative mobility leader. SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - ComfortDelGro Corporation Limited (SGX:C52) (“ComfortDelGro” or, “The Group”) today, unveiled its refreshed corporate brand, comprising a new purpose statement and modern visual identity that signifies a step forward in the company’s evolution into a global multi-modal transport leader. The Group has made significant strides in growing its international business, winning bus and rail tenders in Europe and Australia, as well as building leading positions for its point-to-point mobility businesses in key markets. With a presence in 13 countries, 24,500 employees, an operating fleet of over 54,000 vehicles and a rail network of 343 kilometres in operation and under mobilisation, ComfortDelGro is one of the largest land transport companies in the world. ComfortDelGro Managing Director/Group CEO Cheng Siak Kian said, “Our purpose statement – Mobility for a better future, drives us to reimagine mobility as a catalyst for positive impact as we accelerate our growth and navigate new horizons. It reflects our commitment to addressing the changing needs of our stakeholders as a global multi-modal transport leader. At the same time, it aligns the Group’s diverse operations and workforce under the common goal of building a purpose-driven and values-led organisation.” ComfortDelGro Chairman Mark Greaves added, “The transport landscape is evolving, and so is ComfortDelGro. We are committed to sustainable mobility, powered by innovation and driven by collaboration. This brand refresh underpins our journey forward as a global, progressive, and collaborative mobility company while building on the strong foundation of our businesses and our rich heritage. Our purpose ‘Mobility for a better future’ will guide us as we continue to create long-term value for our stakeholders, shape the future of transportation, and contribute to a more sustainable and connected world." Driven by our new purpose: Mobility for a better futureA modern identityComplementing our purpose statement is an updated ComfortDelGro logo that symbolises the company’s journey forward and its commitment to delivering innovative, world-class mobility solutions. Key elements include:A refined blue hue, representing reliability, trust, and customer confidence.A streamlined lowercase font, conveying approachability and collaboration.An enhanced arrow motif, reinforcing the company’s forward-thinking and dynamic approach.The updated brand and corporate identity will be gradually implemented in stages across the Group’s global operations.Media Assets:High-resolution images can be downloaded here: https://fromsmash.com/cdgbrandrefreshAbout ComfortDelGro CorporationComfortDelGro is a leading multi-modal transport operator offering a comprehensive suite of transportation solutions. Our extensive network spans public transport including buses and rail, point-to-point transport with taxis and private hire cars as well as business-to-business mobility solutions. Every day, millions rely on our services across 13 countries including; Singapore, Australia, the United Kingdom, New Zealand, China, Ireland, Sweden, France, Malaysia, Spain, Portugal, Greece, and the Netherlands. As a global operator, we play an important role in steering the transition towards a low-carbon economy. With about 60% of our owned fleet consisting of cleaner energy vehicles, we support governments and cities in enabling inclusive and sustainable transport systems. For our efforts, ComfortDelGro has been included in the Dow Jones Best-in-Class Indices since 2019, the only Singaporean transport company in the index. Media Contact Information:Group Corporate Communications ComfortDelGro Corporation Limited groupcorpcomms@comfortdelgro.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights For the Year Ended 31 December RMB20242023Change RMB’BillionRMB’Billion(%)Revenue28.8726.20+10.2%Gross profit margin (%)81.5%81.0%+0.5pptSelling and administrative expenses to revenue ratio (%) *42.1%42.2%-0.1pptR&D expenses to revenue ratio (%)17.6%16.8%+0.8pptProfit for the year6.365.10+24.9%Profit attributable to owners of the parent **3.502.33+50.1%Adjusted non-HKFRS profit attributable tothe owners of the parent *** 3.46 2.59 +33.5%Basic earnings per share, based on adjusted non-HKFRS profit attributable to the owner of the parent (RMB cents) 18.90 13.97 +35.3%Sales of innovative products ****12.069.89+21.9%Share of revenue (%)41.8%37.8% Sales of new products*****10.098.05+25.4%Share of revenue (%)35.0%30.7% Dividend per share (HK cents)7.05.0+40.0%- Interim3.02.0+50.0%- Final4.03.0+33.3%*The total of selling and distribution costs and administrative expenses divided by revenue**The significant year-on-year increase in profit attributable to the owners of the parent was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year***It refers to the basic earnings attributable to the owners of the parent after excluding impacts of discontinued operations, certain non-cash items and the share of profits and losses of associates and joint ventures.****Sales is the gross sales amount minus the sales discount. Innovative products include innovative drugs and biosimilars*****Products launched within five yearsDevelopment HighlightsOncology Innovative Drugs- Focus V (Anlotinib Hydrochloride Capsules) has been approved for seven indications. The marketing applications of three new indications have been submitted to the Center for Drug Evaluation of the China National Medical Products Administration (“CDE”), while another three pivotal clinical trials for new indications have shown positive results. The Group will submit new marketing applications to the CDE for these indications in the near future. In addition, anlotinib is in Phase III clinical studies for a number of new indications, including first-line non-squamous non-small cell lung cancer and first-line colorectal cancer. It is expected that marketing applications will be submitted gradually in the next few years.- Yilishu (Efbemalenograstim alfa Injection) has completed three global multi-center, randomized, and controlled pivotal Phase III clinical trials, and has been compared with the commonly used short-acting and long-acting G-CSF drugs in clinical practice, proving its efficacy and safety. In December 2023, Efbemalenograstim alfa was successfully included in the NRDL, and its sales volume accelerated in 2024, becoming an important contributor to the Group’s revenue growth.- Anfangning (Garsorasib Tablets) is a novel and highly effective KRAS G12C inhibitor that was approved for marketing by the NMPA in November 2024 for the treatment of advanced non-small cell lung cancer with KRAS G12C mutation that has received at least one systemic treatment. The Group will further explore the multi-indication potential of garsorasib, which is expected to become another blockbuster product in the oncology field.- Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection), and Paletan (Pertuzumab Injection) were approved for marketing by the NMPA in February 2023, May 2023, July 2023, and December 2024, respectively. The rapid increase in the volume of these biosimilars in 2024 has accelerated the Group’s revenue growth.Liver Disease Innovative Drugs- Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for three indications: chronic viral hepatitis, acute drug-induced liver injury, and improvement of liver dysfunction. Magnesium isoglycyrrhizinate is the world’s first 99.9% purified alpha-glycyrrhizic acid. It has the advantages of strong liver targeting, excellent anti-inflammatory effects, and good safety.- Lanifibranor (pan-PPAR agonist) is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.Respiratory Innovative Drugs- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national Volume-based Procurement (“VBP”). The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP, enabling its sales to achieve steady growth in 2024.- Tianyun (Colistimethate Sodium for Injection) is a first-to-market generic drug launched in 2021. It is China’s first colistimethate sodium for injection approved for marketing, and was successfully included in the NRDL in 2023. At present, only two products with the same generic name have been approved in China. The Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly in 2024.Surgery/Analgesia Innovative Drugs- Zepolas (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth in 2024. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing in 2025.Others- In 2024, the tenth batch of VBP products accounted for only 1% of the Group’s total revenue, and the related risks have basically been removed. In addition, Anboni (Unecritinib Fumarate Capsules) and Anluoqing (Envonalkib Citrate Capsules), two category 1 innovative drugs independently developed by the Group, were newly included in the NRDL and are expected to benefit more patients.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2024.During the year, the Group recorded revenue of approximately RMB28.87 billion, an increase of approximately 10.2% over last year. Profit attributable to the owners of the parent company was approximately RMB3.50 billion, a substantial increase of approximately 50.1% over last year. Earnings per share attributable to the owners of the parent company were approximately RMB19.13 cents, a significant increase of approximately 51.9% over last year, which was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year. Excluding the profit attributable to the owners of the parent from the discontinued operations, the share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests), one-off adjustments for the impairment and fair value changes of certain assets and liabilities (net of related tax and non-controlling interests), fair value losses/(gains) of current equity investments (net of related tax and non-controlling interests), share-based payments (net of related tax and non-controlling interests), effective interest expenses and exchange (gain)/loss of the convertible bond debt component, adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB3.46 billion, an increase of approximately 33.5% over last year. The Group's liquidity remains strong, with total fund reserve at approximately RMB24.11 billion, including cash and bank balances classified under current assets of approximately RMB9.57 billion, bank deposit classified under non-current assets of approximately RMB9.37 billion, and the wealth management products of approximately RMB5.17 billion in aggregate.The Board of Directors has recommended a final dividend payment of HK4 cents per share (2023: HK3 cents). Together with the interim dividend of HK3 cents already paid, the total dividend for the year amounted to HK7 cents (2023: HK5 cents).Sales: Robust sales system continues to drive results Achieves positive revenue growth for generic drugsOn the strong foundation its generic drug business provides, the Group has comprehensively promoted innovation and transformation. The innovative products have kept boosting sales growth, with share of revenue climbing year after year. Revenue from innovative products amounted to RMB12.06 billion, up by 21.9% year-on-year, and accounted for 41.8% of the Group's total revenue.During the year, the sales of oncology medicines amounted to approximately RMB10.73 billion, representing approximately 37.2% of the Group’s revenue. The sales of surgery/analgesia and liver disease amounted to approximately RMB4.46 billion and RMB3.44 billion, respectively, representing approximately 15.4% and 11.9% of the Group's revenue, respectively. In addition, sales contributions from various areas such as respiratory, cardio-cerebral vascular medicines and others have continued to contribute to the Group's revenue. Among them, the sales of respiratory and cardio-cerebral vascular medicines accounted for approximately 10.9% and 7.5% of the Group's revenue, respectively.R&D: Pushes at full force innovative product development Actively applies for various patentsThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver diseases, respiratory and surgery/analgesia. As at the end of the reporting period, the Group had 70 innovative products under development, including 39 oncology products, 7 liver disease products, 13 respiratory products, and 6 surgery/analgesia products, and 5 other products. In addition, the Group had 65 generic drug products in development.The Group also attaches tremendous importance to the protection of intellectual property rights and encourages its member enterprises to file patent applications in order to enhance the Group’s core competitiveness. During the reporting period, the Group filed 1,069 new patent applications and received 349 patent invention approvals. As at the end of the reporting period, the Group had accumulated 5,082 effective patents and patent applications and obtained 1,958 patent invention approvals.Prospects: Focuses on core business and innovation Continues to promote dual-pronged approach in implementing globalization strategyThe Chinese pharmaceutical market has occupied a key position in the global pharmaceutical industry due to its huge volume and increasing market demand. In addition, as a strategic industry closely linked to the national economy and people’s livelihood, the pharmaceutical industry receives key support from national policies and incentives. Meanwhile, a series of policies is expected to broaden the pricing flexibility of innovative drugs, improve their accessibility, and create a wider market prospect for such drugs.Committed to its vision “to be a leading global pharmaceutical company through delivering innovative therapies for patients”, the Group has adhered to comprehensive innovation, stepped up its R&D investment, and continued to strengthen its internal R&D capabilities. It has now built a comprehensive pipeline and product portfolio. At the same time, the Group has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises.At present, the Group has entered the harvest period of its innovative development. It is expected that by 2027, the number of innovative products launched to the market will exceed 30, with revenue from innovative products accounting for over 55% of total revenue. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for the future sustainable growth. In addition, the Group has advanced its digitalization strategy with artificial intelligence (AI) as the core driving force. It has finished locally deploying cutting-edge AI models including DeepSeek and ChatGPT, and optimized key business such as cross-departmental collaboration, thereby significantly improving operational efficiency.Meanwhile, the Group adopts its dual-pronged globalization strategy to accelerate innovation and development. The Group will bring global pharmaceutical innovations to China to benefit Chinese patients, while also expanding its presence in international markets to target unmet clinical needs worldwide.Looking ahead, the Group will further focus on its core business and innovation, and continue to improve R&D efficiency and quality in the four major therapeutic areas. It will also actively accelerate the deployment for globalization of its business to drive rapid business growth and steady performance improvement, and contribute to the development of the global pharmaceutical industry.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for six consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.